申请人:Takeda Chemical Industries, Ltd.
公开号:US05665748A1
公开(公告)日:1997-09-09
Novel 2,4-oxazolidinedione compounds of the formula: ##STR1## wherein R is a hydrocarbon residue or a heterocyclic group each of which may be substituted; Y is --CO--, --CH(OH)-- or --NR.sup.3 -- (wherein R.sup.3 is an alkyl group which may be substituted); m is 0 or 1; n is 0, 1 or 2; X is CH or N; A is bivalent straight or branched hydrocarbon chain residue having 1 to 7 carbon atoms; R.sup.1 and R.sup.2 each are hydrogen or an alkyl group, or R.sup.1 and R.sup.2 are combined with each other to form a 5- to 6-membered heterocyclic group optionally containing nitrogen; L and M each are hydrogen, or L and M are combined with each other to form a bond, or pharmaceutically acceptable salts thereof, having excellent hypoglycemic and hypolipidemic activities and are useful as anti-diabetics or hypolipidemic agents.
2,4-噁唑烷二酮类化合物的化学式如下:##STR1## 其中R是一个烃残基或一个杂环基,每个都可以被取代;Y是--CO--,--CH(OH)--或--NR.sup.3--(其中R.sup.3是一个可以被取代的烷基);m为0或1;n为0, 1或2;X是CH或N;A是具有1至7个碳原子的二价直链或支链烃基残基;R.sup.1和R.sup.2分别是氢或烷基,或R.sup.1和R.sup.2结合在一起形成一个含氮的5至6元杂环基;L和M分别是氢,或L和M结合在一起形成一个键,或其药用盐,具有出色的降糖和降脂活性,并可用作抗糖尿病或降脂药物。